Patient characteristics may help predict clinical outcome in CLL

April 2009
Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p26
The article discusses a study on the role of identifying patient characteristics related to complete response, time to treatment failure and overall survival (OS) in predicting clinical outcome for patients with chronic lymphocytic leukemia (CLL).


Related Articles

  • Using Smudge Cells on Routine Blood Smears to Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test. Nowakowski, Grzegorz S.; Hoyer, James D.; Shanafelt, Tait D.; Geyer, Susan M.; LaPlant, Betsy R.; Call, Timothy G.; Jelinek, Diane F.; Zent, Clive S.; Kay, Nem E. // Mayo Clinic Proceedings;Apr2007, Vol. 82 Issue 4, p449 

    Recently developed prognostic tests In early Rai and Binet stage chronic lymphocytic leukemia (CLL) require considerable technologic expertise and are not available worldwide. Smudge cells are CLL cells ruptured during smear preparation. We hypothesized that smudge cell formation is inversely...

  • Predicting Progression – ZAP-70 in CLL. Hamblin, Terry J. // New England Journal of Medicine;8/26/2004, Vol. 351 Issue 9, p856 

    The article presents an editorial regarding predicting the progression of chronic lymphocytic leukemia (CLL). The 70-kD zeta-associated protein (ZAP-70) is a key signaling molecule for T lymphocytes and natural killer cells. A study by Rassenti and colleagues in this issue of the journal reports...

  • Flow Cytometric Detection of ZAP-70 in Chronic Lymphocytic Leukemia: Correlation With Immunocytochemistry and Western Blot Analysis. Slack, Graham W.; Wizniak, Juanita; Dabbagh, Laith; Xinzhe Shi; Gelebart, Pascal; Lai, Raymond // Archives of Pathology & Laboratory Medicine;Jan2007, Vol. 131 Issue 1, p50 

    Context.—Expression of ZAP-70 in chronic lymphocytic leukemia (CLL) predicts worse clinical outcome in patients with early-stage disease. It has become important to include ZAP-70 in the immunophenotyping panel used to diagnose CLL, commonly performed by flow cytometry (FC). Nevertheless,...

  • Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia. Helwick, Caroline // American Health & Drug Benefits;Feb Special Issue 2012, Vol. 5, p11 

    The article reports on research which was conducted at the University of Texas M. D. Anderson Cancer Center in Houston, Texas to evaluate the effectiveness of a newly developed oral B-cell receptor inhibitor and found that the inhibitor is highly effective in treating chronic lymphocytic leukemia.

  • Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Krause, John R.; Drinkard, Lee C.; Keglovits, Latoya C. // Baylor University Medical Center Proceedings;Jan2013, Vol. 26 Issue 1, p16 

    Transformation to a large cell lymphoma may occur during the course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in approximately 5% of the cases. This is known as Richter's transformation. A much less frequent transformation to Hodgkin lymphoma may occur. We report a...

  • Outcomes in critically ill chronic lymphocytic leukemia patients. Xhaard, Aliénor; Epelboin, Loic; Schnell, David; Vincent, François; Levy, Vincent; Malphettes, Marion; Azoulay, Élie; Darmon, Michaël // Supportive Care in Cancer;Jul2013, Vol. 21 Issue 7, p1885 

    Background: Although recent studies have demonstrated an improvement in the prognosis of critically ill cancer patients, little is known regarding the prognosis of patients with non-aggressive underlying malignancies. The aims of this study were to assess the prognosis of critically ill patients...

  • Correction: Lipoprotein Lipase SNPs rs13702 and rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients. null, null // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    No abstract available.

  • Clustering of Expression Data in Chronic Lymphocytic Leukemia Reveals New Molecular Subdivisions. Yepes, Sally; Torres, Maria Mercedes; Andrade, Rafael E. // PLoS ONE;9/10/2015, Vol. 10 Issue 9, p1 

    Although the identification of inherent structure in chronic lymphocytic leukemia (CLL) gene expression data using class discovery approaches has not been extensively explored, the natural clustering of patient samples can reveal molecular subdivisions that have biological and clinical...

  • De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia. El-Ghammaz, Amro; Abdelwahed, Essam; Mostafa, Nevine; Mansour, Dina // Clinical & Experimental Medicine;Nov2015, Vol. 15 Issue 4, p493 

    To determine the prognostic impact of de novo deletion 17p13.1 (17p-) in previously untreated chronic lymphocytic leukemia (CLL) patients, we prospectively studied the outcome of 71 treatment-naïve CLL patients. About 18.3 % of them had 17p- detected by interphase fluorescent in situ...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics